Iain is the founding Chief Executive Officer of Quell Therapeutics. He has over 25 years of experience in the pharmaceutical and biotech sector. He joined Quell from Jazz Pharmaceuticals where he served on the Executive Committee and as Head of Europe and Rest of World for Jazz Pharmaceuticals plc with responsibility for ex-U.S. operations. Prior to that he served as Chief Commercial Officer of EUSA Pharma, a transatlantic specialty pharmaceutical company based in the UK which was acquired by Jazz Pharmaceuticals. He also served as Vice President and Global Business Manager for Transplantation and Immunology at Wyeth as well as general management and commercial leadership positions with increasing responsibility over thirteen years at Novartis and Roche.  He holds a Bachelor of Science degree in Biochemistry from the University of London.

Luke serves as Vice President Operations & Corporate Development and has broad experience in the pharmaceutical industry. He joined Quell from Neon Therapeutics where he served as Senior Director of Business Development & Strategy working across business development and licensing, strategic planning, R&D programs, as well as supporting the company’s IPO on the Nasdaq Stock Market. In addition, he played a key leadership role in leading and building out Neon’s T cell therapy strategy and pipeline. Prior to joining Neon, Luke was a principal with Boston Consulting Group where he advised global pharma and biotech clients on corporate strategy, M&A, R&D portfolio, drug development, business development and R&D operations. Luke holds an MSci in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD in Molecular and Cellular Oncology from the Institute of Cancer Research, University of London.

Bernd serves as Vice President Product Delivery and has 18 years of industry experience in the pharmaceutical sector, covering a broad range of innovative medicines at different stages in development and post launch. He joined Quell from GSK Stevenage where he served as MPD Leader with overall accountability for the CMC development, governance and end to end supply chain of a portfolio of medicines (small molecules and cell & gene therapies) covering pre-clinical to late-phase development as well as commercial supply, incl. interactions with regulatory bodies.

Prior to that he was the Technical Director and a member of the site leadership team of one of GSK’s main manufacturing facilities in the UK. Before re-joining GSK in 2012 he held roles of increasing responsibility in process and product development at AstraZeneca, UK and India.

Bernd holds a postgraduate degree in Chemical Engineering (MSc+) from the Friedrich-Alexander University of Erlangen, Germany, and is a Fellow of the Institution of Chemical Engineers.

Marc serves as Vice President Biology and has forged a deep academic research career focused on Tregs biology and immunological tolerance. His most recent research as Senior Lecturer at King’s College London has combined pre-clinical models and deep phenotyping of clinical samples to identify new strategies to modulate Treg homeostasis and function. Marc’s group has investigated the role of microenviromental cues such as IL-2 availability and inflammation shaping the phenotypic characteristics of tissue resident T cells. His translational research has supported the implementation of new tolerogenic therapies such as low-dose IL-2 and CAR-Tregs into transplantation and autoimmunity. From a clinical aspect, Marc has led the immunomonitoring analysis of several trials associated on liver transplantation tolerance. Prior to that he worked in Professor Jeff Bluestones lab at University College San Francisco where he carried out post-doctoral research on the transcriptional profile of CD28 signalling in T cell activation and the analysis of Treg phenotypic plasticity in autoimmunity. Marc holds a PhD from the University of Barcelona focussed on the identification of transcriptional and phenotypic biomarkers to predict transplantation tolerance.

Mark serves as the Company’s Director of Finance. He has over 20 years’ experience as a senior finance and operations director in the pharma, biotech and healthcare industries. He joined Quell from Gyroscope Therapeutics, a gene therapy start up and before that worked as a CFO and COO in regional NHS Pathology businesses. Mark also has extensive international finance leadership experience in companies such as Abraxis, Intertek and Baxter Healthcare. He holds a BA in Business Studies and is a member of the Chartered Institute of Management Accountants.

Jodie serves as Head of Intellectual Properly and is a Chartered (UK) and European Patent Attorney with particular experience of intellectual property in the cell and gene therapy field. She joined Quell after more than 4 years acting as the internal patent attorney and Head of Intellectual Property at the Cell and Gene Therapy Catapult, where she was responsible for the patent portfolio and for assessing freedom to operate in a multitude of different areas of cell and gene therapy.  Prior to that, Jodie worked for fourteen years in the biotech team at private practice patent attorney firm Dehns in London, looking after IP on behalf of multinational companies, SMEs and Universities. She has a BSc from Imperial College, London and a PhD in molecular biology from King’s College, London.